Selectively targeting mechanisms thought to be critical to seizure occurrence may expand therapeutic options for refractory epilepsy. This 30-minute program features a summary of key efficacy and safety data of the three third generation AEDs currently registered for use in Australia, clearly differentiating their respective indications for genetic generalised epilepsy and/or focal epilepsy. With a comprehensive case study that focusses on the importance of accurate seizure classification, adjunctive treatment selection and dosing to manage adverse effects, this program also offers expert video commentary from Professor Sam Berkovic to help you optimise your practice.
This interactive online learning activity is valued at 0.5 Hour(s) of continuing education.
Professor Sam Berkovic AC
MD, FRACP, FAA, FAHMS, FRS
Upon completion of this program, participants will be able to:
- Evaluate the efficacy and safety of third generation AEDs
- Describe the broad-spectrum role of perampanel in the treatment of focal seizures with or without secondary generalized seizures (focal to bilateral tonic-clonic seizures in 2017 ILAE terminology) and primary generalized tonic-clonic seizures in idiopathic generalised epilepsy (genetic generalised epilepsy in 2017 ILAE terminology)
- Describe how to optimize perampanel dosing to help minimize adverse effects